aspirin has been researched along with Aspirin Induced Asthma in 246 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to compare the clinical and biochemical responses to chronic oral AD in 20 patients with AIA and 14 patients with aspirin-tolerant asthma (ATA)." | 9.19 | Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme." | 9.12 | The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021) |
| "Aspirin-exacerbated respiratory disease (AERD) is a phenotype of severe asthma, but its disease course has not been well documented compared with that of aspirin-tolerant asthma (ATA)." | 8.31 | Long-term clinical outcomes of aspirin-exacerbated respiratory disease: Real-world data from an adult asthma cohort. ( Kim, C; Lee, E; Lee, HY; Lee, Y; Park, HS; Park, RW; Woo, SD; You, SC, 2023) |
| "Clinical features of aspirin-exacerbated respiratory disease (AERD) are characterized by overproduction of cysteinyl leukotrienes (LT) and eosinophil activation, in which epithelial cells contribute to eosinophilic airway inflammation." | 7.88 | Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease. ( Choi, Y; Kim, HM; Kim, SH; Park, HS; Pham, DL; Trinh, HKT, 2018) |
| " Aspirin-exacerbated respiratory disease (AERD) is defined as asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase-1 inhibitors." | 7.85 | Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease. ( Johal, K; Peters, A; Welch, K, 2017) |
| " In aspirin exacerbated respiratory disease (AERD), asthmatic symptoms are precipitated by ingestion of non-steroid anti-inflammatory drugs capable for pharmacologic inhibition of cyclooxygenase-1 isoenzyme." | 7.81 | Aspirin provocation increases 8-iso-PGE2 in exhaled breath condensate of aspirin-hypersensitive asthmatics. ( Celejewska-Wójcik, N; Gielicz, A; Januszek, R; Kaszuba, M; Mastalerz, L; Oleś, K; Plutecka, H; Sanak, M; Stręk, P; Wójcik, K, 2015) |
| "Aspirin-exacerbated respiratory disease (AERD) has attracted a great deal of attention because of its association with increased asthma severity." | 7.80 | Plasma apolipoprotein H levels are different between aspirin induced respiratory diseases and aspirin tolerant asthma. ( Heo, JS; Kim, HJ; Moon, KY; Park, CS; Park, JS, 2014) |
| "Aspirin sensitivity syndrome is an underdiagnosed entity in pediatric otolaryngology." | 7.79 | Aspirin sensitivity syndrome (Samter's Triad): an unrecognized disorder in children with nasal polyposis. ( Chen, BS; Manning, SC; Parikh, SR; Virant, FS, 2013) |
| "There is no in vitro test to diagnose aspirin-intolerant asthma (AIA)." | 7.78 | Challenge of isolated sputum cells supports in vivo origin of intolerance reaction to aspirin/non-steroidal anti-inflammatory drugs in asthma. ( Daham, K; Dahlén, B; Dahlén, SE; Delin, I; Gaber, F; Gyllfors, P; Higashi, A; Higashi, N; James, A; Kumlin, M; Lindeberg, A; Skedinger, M, 2012) |
| "Despite the need for further functional evaluations and replications, we conclude that DDR1 polymorphisms are not likely to contribute to predispositions of AERD, but may be potentially associated with FEV(1) decline by aspirin provocation in asthmatics." | 7.78 | Potential association of DDR1 genetic variant with FEV1 decline by aspirin provocation in asthmatics. ( Bae, JS; Cho, SH; Choi, BW; Choi, IS; Kim, JH; Kim, JY; Kim, MK; Kim, YH; Park, BL; Park, CS; Park, JS; Pasaje, CF; Shin, HD; Uh, ST, 2012) |
| "A considerable number of asthmatic patients with no history of aspirin intolerance responded to the inhalation aspirin challenge." | 7.76 | Airway responsiveness to inhaled aspirin is influenced by airway hyperresponsiveness in asthmatic patients. ( Choi, IS; Han, ER; Kim, CS; Kim, DE; Kim, S; Kim, YJ; Park, DJ, 2010) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by eosinophilic rhinosinusitis, nasal polyposis, and bronchial asthma, along with the onset of respiratory reactions after the ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (ASA)." | 5.41 | Effect of low salicylate diet on clinical and inflammatory markers in patients with aspirin exacerbated respiratory disease - a randomized crossover trial. ( Patel, KB; Rocha, T; Rotenberg, BW; Schmerk, C; Sommer, DD; Sowerby, LJ, 2021) |
| "Aspirin exacerbated respiratory disease (AERD) is a condition caused by increased bronchoconstriction in people with asthma after taking aspirin or another NSAID." | 5.41 | Aspirin-Exacerbated Respiratory Disease Polymorphisms; a review study. ( Abyaneh, FA; Darabi, B; Ebrahimi, M; Fathollahpour, A; Kalmarzi, RN; Kooti, W, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by abnormal arachidonic acid metabolism leading to chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, and upper and/or lower respiratory symptoms after ingestion of cyclooxygenase-1 inhibiting nonsteroidal antiinflammatory drugs." | 5.41 | Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review. ( Choby, G; Divekar, RD; Hagan, JB; O'Brien, EK; Pinheiro-Neto, CD; Stokken, JK; Walters, BK; Willson, TJ, 2023) |
| "Oral provocation tests with aspirin are important for diagnosis and management in adult and pediatric populations with reported NSAID hypersensitivity." | 5.41 | Recent Updates in Understanding NSAID Hypersensitivity. ( Cahill, K; Minaldi, E, 2023) |
| "Aspirin therapy after desensitization (ATAD) and respiratory biologic therapies targeting interleukin (IL)-4Rα, IL-5, IL-5Rα, and immunoglobulin E, all have some efficacy in the treatment of CRSwNP and asthma in patients with AERD." | 5.41 | Aspirin-exacerbated respiratory disease: Updates in the era of biologics. ( Buchheit, KM; Mullur, J, 2023) |
| "We investigated whether omalizumab administration would be associated with attenuation of aspirin-provoked bronchospasm in patients with AERD undergoing aspirin desensitization." | 5.27 | Omalizumab can inhibit respiratory reaction during aspirin desensitization. ( Aronica, MA; Hazen, SL; Lang, DM; Maierson, ES; Vasas, DC; Wang, XF, 2018) |
| "We sought to compare the clinical and biochemical responses to chronic oral AD in 20 patients with AIA and 14 patients with aspirin-tolerant asthma (ATA)." | 5.19 | Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. ( Bochenek, G; Ćmiel, A; Gielicz, A; Niżankowska-Mogilnicka, E; Plutecka, H; Sanak, M; Stręk, P; Świerczyńska-Krępa, M; Szczeklik, A, 2014) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by the clinical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications that inhibit the cycloxgenase-1 enzyme." | 5.12 | The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, ( Baptist, AP; Borish, L; Bosso, JV; Buchheit, KM; Cahill, KN; Campo, P; Cho, SH; Jerschow, E; Keswani, A; Laidlaw, TM; Levy, JM; Nanda, A; Stevens, WW; White, AA, 2021) |
| "Aspirin-exacerbated respiratory disease (AERD) is a condition composed of chronic rhinosinusitis with nasal polyposis and asthma that is defined by respiratory hypersensitivity reactions to the cyclooxygenase 1-inhibitory effects of nonsteroidal anti-inflammatory drugs." | 5.12 | Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease. ( Haque, R; Hopkins, C; Jackson, DJ; White, AA, 2021) |
| "Aspirin-exacerbated respiratory disease (AERD) is characterized by eosinophilic chronic rhinosinusitis with nasal polyps, asthma, and upper-/lower-respiratory tract reactions to nonsteroidal antiinflammatory drugs." | 5.05 | Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease. ( Luskin, K; Thakrar, H; White, A, 2020) |
| "Aspirin-exacerbated respiratory disease (AERD) represents an aggressive form of chronic rhinosinusitis with nasal polyposis that is notoriously challenging to treat." | 5.05 | Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review. ( Chin, CJ; Larivée, N, 2020) |
| "Aspirin-exacerbated respiratory disease is a chronic and treatment-resistant disease, characterized by the presence of eosinophilic rhinosinusitis, nasal polyposis, bronchial asthma, and nonsteroidal anti-inflammatory drugs hypersensitivity." | 4.98 | Aspirin exacerbated respiratory disease: Current topics and trends. ( Guaní-Guerra, E; Moreno-Paz, FJ; Rodríguez-Jiménez, JC; Terán, LM, 2018) |
| "The literature indicates that patients with coronary artery disease (CAD), including those with an acute coronary syndrome, may safely undergo low-dose aspirin challenge and/or desensitization." | 4.95 | Aspirin challenge and desensitization: how, when and why. ( Caruso, C; Cortellini, G; Romano, A, 2017) |
| "Aspirin-exacerbated respiratory disease is defined by the clinical tetrad of aspirin sensitivity, nasal polyps, asthma, and chronic rhinosinusitis." | 4.93 | Current complications and treatment of aspirin-exacerbated respiratory disease. ( Cook, KA; Stevenson, DD, 2016) |
| "Aspirin-exacerbated respiratory disease is a clinical entity comprising chronic rhinosinusitis with nasal polyposis, asthma and intolerance to COX-1 inhibiting drugs." | 4.91 | Aspirin-exacerbated respiratory disease: characteristics and management strategies. ( Dazy, KM; Simon, RA; Waldram, JD, 2015) |
| "Aspirin desensitization (AD) is effective in relieving asthma and sinonasal outcomes in patients with non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD)." | 4.31 | Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease. ( Anadolu, Y; Atmiş, EÖ; Aydin, Ö; Çelik, GE; Yorulmaz, İ, 2023) |
| "A total of 30 patients with AERD, 30 chronic rhinosinusitis (CRS) with NP patients without aspirin sensitivity (CRSwNP), and 30 control subjects without inflammation of the nasal mucosa (C), selected for surgical treatment entered the study." | 4.31 | Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity. ( Cvetković, G; Gaćeša, D; Perić, A; Vojvodić, D, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is a unique and often clinically severe disease affecting a subgroup of adults with asthma and chronic rhinosinusitis with nasal polyposis." | 4.31 | Mechanistic and clinical updates in AERD: 2021-2022. ( Cahill, KN; Stevens, WW, 2023) |
| "Aspirin-exacerbated respiratory disease (AERD) is a phenotype of severe asthma, but its disease course has not been well documented compared with that of aspirin-tolerant asthma (ATA)." | 4.31 | Long-term clinical outcomes of aspirin-exacerbated respiratory disease: Real-world data from an adult asthma cohort. ( Kim, C; Lee, E; Lee, HY; Lee, Y; Park, HS; Park, RW; Woo, SD; You, SC, 2023) |
| "Platelets are key contributors to allergic asthma and aspirin-exacerbated respiratory disease (AERD), an asthma phenotype involving platelet activation and IL-33-dependent mast cell activation." | 4.31 | Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease. ( Amin, T; Boyce, JA; Cahill, KN; Feng, C; Foer, D; Hayashi, H; Lai, J; Laidlaw, TM; Lin, A; Liu, T; McGill, A; Nagai, J; Newcomb, DC; Niswender, KD; Snyder, WE; Tani, Y, 2023) |
| "Patients with AERD are at higher risk of ASCVD than patients with asthma and CRSwNP or CRS without nasal polyps, underscoring the need for early ASCVD screening and a consideration for aspirin desensitization or use of a nonaspirin antiplatelet agent in the setting of AERD and comorbid ASCVD." | 4.31 | Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data. ( Adame, MJ; Kuo, YF; Raji, M; Shan, Y; Tripple, JW; Zhang, Y, 2023) |
| "The impact of anosmia on quality-of-life (QoL) for patients with aspirin-exacerbated respiratory disease (AERD) is poorly understood." | 4.12 | Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life. ( Bensko, JC; Buchheit, KM; Gakpo, D; Laidlaw, TM; Lundberg, M; Maurer, R; Mullur, J; Tchekmedyian, R, 2022) |
| "To investigate the safety and outcomes of two-step outpatient NSAID challenges to evaluate patients with non-aspirin-exacerbated respiratory disease (AERD)-related NSAID hypersensitivity." | 4.12 | Safety, Outcomes, and Recommendations for Two-Step Outpatient Nonsteroidal Anti-Inflammatory Drug Challenges. ( Bensko, J; Buchheit, K; Laidlaw, TM; Li, L; Saff, RR, 2022) |
| "Aspirin-exacerbated respiratory disease (AERD) is a syndrome characterised by chronic rhinosinusitis, nasal polyps, asthma and aspirin intolerance." | 4.02 | Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD). ( de Graaf, J; Gratziou, C; Jiménez-Chobillon, MA; Porras Gutiérrez de Velasco, R; Priyadharshini, VS; Ramírez-Jiménez, F; Teran, LM, 2021) |
| "Aspirin-exacerbated respiratory disease (AERD) represents a severe endotype of chronic rhinosinusitis with nasal polyposis." | 3.96 | Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization. ( Cottrell, J; Grose, E; Lee, DJ; Lee, JK; Lee, JM; Sykes, J; Yip, J, 2020) |
| "Aspirin-exacerbated respiratory disease (AERD) refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and acute respiratory tract reactions to ingestion of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)." | 3.96 | Aspirin-exacerbated respiratory disease: longitudinal assessment of a large cohort and implications of diagnostic delay. ( Chou, DW; Kshirsagar, RS; Liang, J; Wei, J, 2020) |
| "Aspirin-exacerbated respiratory disease (AERD) is a severe form of chronic rhinosinusitis with nasal polyps (CRSwNP) accompanied by asthma and an aspirin intolerance." | 3.96 | The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data. ( Eder, K; Gellrich, D; Gröger, M; Högerle, C; Pfrogner, E; San Nicoló, M, 2020) |
| "Background Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis." | 3.88 | Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease. ( Waldram, JD; Walters, KM; White, AA; Woessner, KM, 2018) |
| "Clinical features of aspirin-exacerbated respiratory disease (AERD) are characterized by overproduction of cysteinyl leukotrienes (LT) and eosinophil activation, in which epithelial cells contribute to eosinophilic airway inflammation." | 3.88 | Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease. ( Choi, Y; Kim, HM; Kim, SH; Park, HS; Pham, DL; Trinh, HKT, 2018) |
| "Oral aspirin challenge (OAC) reveals aspirin-exacerbated respiratory disease (AERD) in approximately 50% of unselected patients with chronic rhinosinusitis with nasal polyposis (CRSwNP)." | 3.85 | Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study. ( Gudziol, V; Hummel, T; Koschel, D; Michel, M; Sonnefeld, C, 2017) |
| " Aspirin-exacerbated respiratory disease (AERD) is defined as asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase-1 inhibitors." | 3.85 | Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease. ( Johal, K; Peters, A; Welch, K, 2017) |
| "There is a genetic association between polymorphisms of genes involved in the synthesis of proteins related to arachidonic acid metabolism (LTC4S, ALOX5), antigen presentation (HLA), inflammation (IL5, IL17), and aspirin metabolism (CYP2C19)." | 3.85 | Physiopathology and genetics in aspirin-exacerbated respiratory disease. ( Falfán-Valencia, R; Pavón-Romero, GF; Ramírez-Jiménez, F; Roldán-Alvarez, MA; Terán, LM, 2017) |
| "Fibroblasts were obtained from nasal mucosa; samples of control subjects (NM-C, n = 8) and from nasal polyps from patients with aspirin-exacerbated respiratory disease (NP-AERD, n = 8)." | 3.83 | Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease. ( Alobid, I; Gabasa, M; Machado-Carvalho, L; Martín, M; Mullol, J; Picado, C; Pujols, L; Roca-Ferrer, J; Torres, R, 2016) |
| " Samter's triad consists of nasal polyps, asthma, and aspirin (or nonsteroidal anti-inflammatory drug) sensitivity." | 3.83 | A Case of Kounis Type I in a Young Woman With Samter's Triad. ( Chou, A; Rayner-Hartley, E; Saw, J; Sedlak, T, 2016) |
| " Prior known oral NSAIDs hypersensitivity included aspirin (5), mefenamic acid (2), diclofenac (2), Synflex (2) and ibuprofen (1)." | 3.83 | Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link. ( Hsu, AAL; Tan, JHY, 2016) |
| "Aspirin-exacerbated respiratory disease (AERD) is an endotype of severe and eosinophilic adult asthma characterized by chronic rhinosinusitis with nasal polyps and hypersensitivity to aspirin and/or nonsteroidal anti-inflammatory drugs." | 3.81 | Dipeptidyl-peptidase 10 as a genetic biomarker for the aspirin-exacerbated respiratory disease phenotype. ( Choi, H; Kim, SH; Park, HS; Ye, YM; Yoon, MG, 2015) |
| " In aspirin exacerbated respiratory disease (AERD), asthmatic symptoms are precipitated by ingestion of non-steroid anti-inflammatory drugs capable for pharmacologic inhibition of cyclooxygenase-1 isoenzyme." | 3.81 | Aspirin provocation increases 8-iso-PGE2 in exhaled breath condensate of aspirin-hypersensitive asthmatics. ( Celejewska-Wójcik, N; Gielicz, A; Januszek, R; Kaszuba, M; Mastalerz, L; Oleś, K; Plutecka, H; Sanak, M; Stręk, P; Wójcik, K, 2015) |
| "Aspirin-exacerbated respiratory disease (AERD), formerly known as Samter's Triad, is a syndrome of airway inflammation characterized by rhinosinusitis with polyposis, asthma, and nonsteroidal anti-inflammatory drug (NSAID) intolerance." | 3.81 | Samter's Triad to Aspirin-Exacerbated Respiratory Disease: Historical Perspective and Current Clinical Practice. ( Krouse, HJ; Krouse, JH, 2015) |
| "Aspirin-exacerbated respiratory disease (AERD) has attracted a great deal of attention because of its association with increased asthma severity." | 3.80 | Plasma apolipoprotein H levels are different between aspirin induced respiratory diseases and aspirin tolerant asthma. ( Heo, JS; Kim, HJ; Moon, KY; Park, CS; Park, JS, 2014) |
| "Aspirin-exacerbated respiratory disease (AERD) has been recognized in adults with chronic asthma." | 3.79 | Samter's triad in childhood: a warning for those prescribing NSAIDs. ( Ameratunga, R; Anderson, BJ; Dalziel, S; Randall, N, 2013) |
| "Gene expression analysis revealed that tissue from both aspirin-tolerant subjects and patients with AERD display a TH2 cytokine signature; however, AERD was distinguished from chronic hyperplastic eosinophilic sinusitis by the prominent expression of IFN-γ." | 3.79 | Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease. ( Borish, L; Huyett, P; Liu, L; Negri, J; Payne, SC; Steinke, JW, 2013) |
| "Aspirin sensitivity syndrome is an underdiagnosed entity in pediatric otolaryngology." | 3.79 | Aspirin sensitivity syndrome (Samter's Triad): an unrecognized disorder in children with nasal polyposis. ( Chen, BS; Manning, SC; Parikh, SR; Virant, FS, 2013) |
| "There is no in vitro test to diagnose aspirin-intolerant asthma (AIA)." | 3.78 | Challenge of isolated sputum cells supports in vivo origin of intolerance reaction to aspirin/non-steroidal anti-inflammatory drugs in asthma. ( Daham, K; Dahlén, B; Dahlén, SE; Delin, I; Gaber, F; Gyllfors, P; Higashi, A; Higashi, N; James, A; Kumlin, M; Lindeberg, A; Skedinger, M, 2012) |
| "Aspirin-exacerbated respiratory disease (AERD) is associated with severe asthma and aspirin can cause asthma to worsen, often in the form of a severe and sudden attack." | 3.78 | Differential gene expression profile in PBMCs from subjects with AERD and ATA: a gene marker for AERD. ( An, S; Kim, YJ; Oh, T; Park, CS; Park, JS; Shin, S, 2012) |
| "We enrolled 171 patients with AERD, 229 patients with aspirin-tolerant asthma, and 195 normal healthy controls in a Korean population." | 3.78 | Effect of genetic polymorphism of ALOX15 on aspirin-exacerbated respiratory disease. ( Jin, HJ; Kim, SH; Park, HS; Song, YS; Yang, EM, 2012) |
| "The aim of the present study was to develop a diagnostic set of single-nucleotide polymorphisms (SNPs) for discriminating aspirin-exacerbated respiratory disease (AERD) from aspirin-tolerant asthma (ATA) using the genome-wide association study (GWAS) data; the GWAS data were filtered according to p-values and odds ratios (ORs) using PLINK software, and the 10 candidate SNPs most closely associated with AERD were selected, based on 100 AERD and 100 ATA subjects." | 3.78 | A highly sensitive and specific genetic marker to diagnose aspirin-exacerbated respiratory disease using a genome-wide association study. ( Choi, BW; Choi, IS; Kim, MK; Kim, YJ; Park, BL; Park, CS; Park, J; Shin, H; Shin, SW; Uh, ST, 2012) |
| "Aspirin-exacerbated respiratory disease (AERD) is a unique syndrome of airway inflammation that frequently occurs in patients with nasal polyposis, chronic sinusitis, and asthma." | 3.78 | Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. ( Stevenson, DD; White, AA, 2012) |
| "Despite the need for further functional evaluations and replications, we conclude that DDR1 polymorphisms are not likely to contribute to predispositions of AERD, but may be potentially associated with FEV(1) decline by aspirin provocation in asthmatics." | 3.78 | Potential association of DDR1 genetic variant with FEV1 decline by aspirin provocation in asthmatics. ( Bae, JS; Cho, SH; Choi, BW; Choi, IS; Kim, JH; Kim, JY; Kim, MK; Kim, YH; Park, BL; Park, CS; Park, JS; Pasaje, CF; Shin, HD; Uh, ST, 2012) |
| " To carry out a case-control analysis between AGT and aspirin-induced bronchospasm following treatment with an anti-asthma drug, montelukast (MLK), 38 single nucleotide polymorphisms (SNPs) in AGT were genotyped in 56 AIA cohort." | 3.77 | Association of the variants in AGT gene with modified drug response in Korean aspirin-intolerant asthma patients. ( Bae, JS; Cheong, HS; Kim, JH; Kim, JM; Kim, Y; Lee, JS; Park, BL; Park, CS; Park, JS; Park, TJ; Pasaje, CF; Shin, HD, 2011) |
| "Twenty patients with aspirin induced asthma (ASA-S) and 10 controls (ASA-NS group: 5 patients with allergic rhinitis and 5 healthy subjects) were included." | 3.76 | [Acoustic rhinometry in the evaluation of intranasal aspirin challenge]. ( Bocheńska-Marciniak, M; Kuna, P; Kupczyk, M; Kupryś-Lipińska, I, 2010) |
| "A considerable number of asthmatic patients with no history of aspirin intolerance responded to the inhalation aspirin challenge." | 3.76 | Airway responsiveness to inhaled aspirin is influenced by airway hyperresponsiveness in asthmatic patients. ( Choi, IS; Han, ER; Kim, CS; Kim, DE; Kim, S; Kim, YJ; Park, DJ, 2010) |
| " Cyclooxygenase 2 inhibitors are a safe alternative in patients with AERD." | 2.76 | Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease. ( Bartra, J; Muñoz-Cano, R; Picado, C; Roca, J; Sánchez-López, J; Serrano, C; Valero, A, 2011) |
| " In addition, most studies reported a decline in corticosteroid dosage (oral and inhaled)." | 2.66 | Safety and Efficacy of Aspirin Desensitization Combined With Long-Term Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease. ( Li, R; Luo, F, 2020) |
| "Aspirin therapy is a unique treatment consideration for patients with AERD." | 2.55 | Aspirin-Exacerbated Respiratory Disease. ( Hwang, PH; Walgama, ES, 2017) |
| "Ifetroban was well tolerated in AERD and did not change the mean 2-point increase in Total Nasal Symptom Score (P = ." | 1.91 | Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease. ( Boyce, JA; Buchheit, KM; Cahill, KN; Chen, CC; Cho, L; Cui, J; Feng, C; Hacker, J; Israel, E; Laidlaw, TM; Le, M, 2023) |
| "Treatment of aspirin-exacerbated respiratory disease (AERD) includes endoscopic sinus surgery (ESS) and aspirin desensitization (AD) with aspirin therapy after desensitization (ATAD)." | 1.62 | Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease. ( Adappa, ND; Bosso, JV; Civantos, AM; Corr, AM; Gleeson, PK; Ig-Izevbekhai, KI; Kohanski, MA; Kumar, A; Lin, TC; Locke, TB; Palmer, JN; Sweis, AM, 2021) |
| " Bivariate correlation and multivariate logistic regression were used to analyze associations between patient characteristics and need for repeated dosing of aspirin." | 1.48 | Factors correlated with repeated aspirin dosing during aspirin desensitization. ( Baldwin, JL; Baptist, AP; Schuler, CF, 2018) |
| "Aspirin-treated and COX-1 knockout (KO) mice showed significantly lower accumulation of PMN-MDSCs in the inflamed lung and immune organs accompanied by increased TH2 airway responses." | 1.40 | Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice. ( Bao, Y; Funk, CD; Kong, D; Shen, Y; Shi, G; Shi, M; Tang, J; Wang, H; Wang, Q; Wang, T; Xiao, B; Yu, Y; Zhou, J; Zuo, C, 2014) |
| "A treatment with aspirin in the human bronchial epithelial cells increased the mRNA expression level of KIF3A compared to that of the untreated control (P ≤ 0." | 1.37 | KIF3A, a cilia structural gene on chromosome 5q31, and its polymorphisms show an association with aspirin hypersensitivity in asthma. ( Bae, JS; Cha, JY; Cheong, HS; Cho, SH; Choi, IS; Jang, AS; Kim, JH; Kim, MK; Park, BL; Park, CS; Park, JS; Shin, HD; Uh, ST, 2011) |
| " Our results identify the decreased expression of prostaglandin H synthase 1 and increased expression of leukotriene C(4) synthase as the key elements in AA metabolism that contribute to increased leukotriene C(4) and decreased anti-inflammatory prostaglandins after NSAID dosing in aspirin-intolerant patients." | 1.37 | Role of expression of prostaglandin synthases 1 and 2 and leukotriene C4 synthase in aspirin-intolerant asthma: a theoretical study. ( Brumen, M; Dobovišek, A; Fajmut, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (1.63) | 29.6817 |
| 2010's | 141 (57.32) | 24.3611 |
| 2020's | 101 (41.06) | 2.80 |
| Authors | Studies |
|---|---|
| Wangberg, H | 3 |
| Spierling Bagsic, SR | 2 |
| Osuna, L | 1 |
| White, AA | 19 |
| D'Souza, GE | 1 |
| Nwagu, U | 1 |
| Barton, B | 1 |
| Unsal, AA | 1 |
| Rabinowitz, MR | 1 |
| Rosen, MR | 1 |
| Nyquist, GG | 1 |
| Cohn, J | 1 |
| Most, J | 1 |
| Toskala, EM | 1 |
| Sehanobish, E | 3 |
| Asad, M | 2 |
| Jerschow, E | 9 |
| Talat, R | 1 |
| Gengler, I | 1 |
| Phillips, KM | 1 |
| Caradonna, DS | 1 |
| Gray, ST | 1 |
| Sedaghat, AR | 2 |
| Li, L | 1 |
| Bensko, J | 2 |
| Buchheit, K | 2 |
| Saff, RR | 1 |
| Laidlaw, TM | 27 |
| Patel, PP | 1 |
| Cui, J | 3 |
| Cahill, KN | 17 |
| Patel, P | 1 |
| Bensko, JC | 9 |
| Bhattacharyya, N | 2 |
| Buchheit, KM | 14 |
| Tripathi, SH | 3 |
| Kumar, A | 5 |
| Kohanski, MA | 8 |
| Kennedy, DW | 3 |
| Palmer, JN | 10 |
| Adappa, ND | 10 |
| Bosso, JV | 14 |
| Ramos, CL | 2 |
| Woessner, KM | 4 |
| Chu, DK | 2 |
| Stevens, WW | 3 |
| Wu, P | 2 |
| Milne, GL | 2 |
| Amin, T | 2 |
| Singer, J | 4 |
| Murphy, K | 3 |
| Lewis, E | 1 |
| Gapko, D | 1 |
| Boyce, JA | 9 |
| Tan, LH | 1 |
| Lin, C | 1 |
| Ungerer, H | 1 |
| Qatanani, A | 1 |
| Reed, D | 1 |
| Cohen, NA | 2 |
| Miss Ozuna, L | 1 |
| Ryan, T | 2 |
| Mullur, J | 3 |
| Steger, CM | 1 |
| Gakpo, D | 3 |
| Maurer, R | 4 |
| Sanak, M | 9 |
| Corey, KB | 2 |
| Turner, JH | 1 |
| Chowdhury, NI | 1 |
| Chandra, RK | 1 |
| Li, P | 1 |
| Bangert, C | 1 |
| Villazala-Merino, S | 1 |
| Fahrenberger, M | 1 |
| Krausgruber, T | 1 |
| Bauer, WM | 1 |
| Stanek, V | 1 |
| Campion, NJ | 1 |
| Bartosik, T | 1 |
| Quint, T | 1 |
| Regelsberger, G | 1 |
| Niederberger-Leppin, V | 1 |
| Bock, C | 1 |
| Schneider, S | 1 |
| Eckl-Dorna, J | 1 |
| Sohail, A | 1 |
| Hacker, J | 3 |
| Taliaferro, F | 1 |
| Ordovas-Montanes, J | 1 |
| Tchekmedyian, R | 1 |
| Lundberg, M | 1 |
| Bentabol-Ramos, G | 1 |
| Saenz de Santa Maria-Garcia, R | 1 |
| Vidal-Diaz, M | 1 |
| Eguiluz-Gracia, I | 1 |
| Testera-Montes, A | 1 |
| Pitlick, MM | 2 |
| Pongdee, T | 1 |
| Suikkila, A | 1 |
| Lyly, A | 1 |
| Hafrén, L | 1 |
| Saarinen, R | 1 |
| Klockars, T | 1 |
| McGill, A | 3 |
| Palumbo, M | 1 |
| Ghiasi, Y | 1 |
| Bagsic, SRS | 1 |
| White, A | 4 |
| Lee, JU | 3 |
| Kim, MK | 13 |
| Park, SL | 1 |
| Bae, DJ | 3 |
| Chang, HS | 4 |
| Park, CS | 20 |
| Park, JS | 15 |
| Aydin, Ö | 1 |
| Atmiş, EÖ | 1 |
| Anadolu, Y | 1 |
| Yorulmaz, İ | 1 |
| Çelik, GE | 2 |
| Walters, BK | 1 |
| Hagan, JB | 1 |
| Divekar, RD | 1 |
| Willson, TJ | 1 |
| Stokken, JK | 1 |
| Pinheiro-Neto, CD | 1 |
| O'Brien, EK | 1 |
| Choby, G | 1 |
| Esmaeilzadeh, H | 2 |
| Zare, M | 1 |
| Alyasin, S | 1 |
| Nabavizadeh, H | 1 |
| Mortazavi, N | 2 |
| Kanannejad, Z | 1 |
| Minaldi, E | 1 |
| Cahill, K | 2 |
| Perić, A | 1 |
| Gaćeša, D | 1 |
| Cvetković, G | 1 |
| Vojvodić, D | 1 |
| Tao, M | 1 |
| Roberts, S | 1 |
| Arnold, M | 1 |
| Candelo, E | 1 |
| McCalla, M | 1 |
| Valderrama, OA | 1 |
| Avila-Castano, K | 1 |
| Chelf, C | 1 |
| Olomu, O | 1 |
| Donaldson, AM | 1 |
| Hayashi, H | 5 |
| Fukutomi, Y | 6 |
| Mitsui, C | 5 |
| Kajiwara, K | 4 |
| Watai, K | 3 |
| Tomita, Y | 2 |
| Kamide, Y | 3 |
| Tsuburai, T | 4 |
| Sekiya, K | 5 |
| Ishii, M | 1 |
| Hasegawa, Y | 2 |
| Taniguchi, M | 9 |
| Fathollahpour, A | 1 |
| Abyaneh, FA | 1 |
| Darabi, B | 1 |
| Ebrahimi, M | 1 |
| Kooti, W | 1 |
| Kalmarzi, RN | 1 |
| Cho, L | 1 |
| Feng, C | 2 |
| Chen, CC | 1 |
| Le, M | 1 |
| Israel, E | 3 |
| Thakrar, H | 2 |
| Walters, K | 2 |
| Waldram, J | 2 |
| Lee, Y | 1 |
| Kim, C | 1 |
| Lee, E | 1 |
| Lee, HY | 1 |
| Woo, SD | 1 |
| You, SC | 1 |
| Park, RW | 1 |
| Park, HS | 8 |
| Supron, AD | 1 |
| Bergmark, RW | 1 |
| Roditi, RE | 1 |
| Panara, K | 1 |
| Grose, E | 2 |
| Lee, DJ | 3 |
| Safadi, J | 1 |
| Douglas, JE | 2 |
| Lee, JM | 4 |
| Adame, MJ | 1 |
| Raji, M | 1 |
| Shan, Y | 1 |
| Zhang, Y | 1 |
| Kuo, YF | 2 |
| Tripple, JW | 1 |
| Herzberg, SD | 1 |
| Bosso, AM | 1 |
| Sangal, NR | 1 |
| Badrani, JH | 2 |
| Cavagnero, K | 1 |
| Eastman, JJ | 1 |
| Kim, AS | 1 |
| Strohm, A | 1 |
| Yan, C | 1 |
| Deconde, A | 1 |
| Zuraw, BL | 2 |
| Christiansen, SC | 2 |
| Doherty, TA | 3 |
| Kim, SL | 1 |
| Rank, MA | 1 |
| Peters, AT | 1 |
| Foer, D | 1 |
| Nagai, J | 1 |
| Tani, Y | 1 |
| Liu, T | 1 |
| Newcomb, DC | 1 |
| Lai, J | 1 |
| Snyder, WE | 1 |
| Lin, A | 1 |
| Niswender, KD | 1 |
| Lee, SE | 1 |
| Farquhar, DR | 1 |
| Adams, KN | 1 |
| Masood, MM | 1 |
| Senior, BA | 1 |
| Thorp, BD | 2 |
| Zanation, AM | 2 |
| Ebert, CS | 2 |
| Jean, T | 1 |
| Eng, V | 1 |
| Sheikh, J | 1 |
| Kaplan, MS | 1 |
| Goldberg, B | 1 |
| Jau Yang, S | 1 |
| Samant, S | 1 |
| Lee, KM | 1 |
| Schünemann, HJ | 1 |
| Szczeklik, W | 1 |
| Shah, SJ | 1 |
| Abuzeid, WM | 1 |
| Ponduri, A | 1 |
| Pelletier, T | 3 |
| Ren, Z | 3 |
| Keskin, T | 1 |
| Roizen, G | 2 |
| Rosenstreich, D | 3 |
| Ferastraoaru, D | 1 |
| Eid, RC | 3 |
| Palumbo, ML | 2 |
| Wudneh, E | 1 |
| Zahid, S | 1 |
| San Nicoló, M | 2 |
| Högerle, C | 1 |
| Gellrich, D | 1 |
| Eder, K | 1 |
| Pfrogner, E | 1 |
| Gröger, M | 1 |
| Luskin, KT | 1 |
| Simon, RA | 4 |
| Larivée, N | 1 |
| Chin, CJ | 1 |
| Studer, MB | 1 |
| Roland, LT | 1 |
| Ochsner, MC | 1 |
| Cox, D | 1 |
| DelGaudio, JM | 1 |
| Wise, SK | 1 |
| Levy, JM | 9 |
| Kshirsagar, RS | 1 |
| Chou, DW | 1 |
| Wei, J | 1 |
| Liang, J | 1 |
| Nakamura, Y | 1 |
| Hamada, Y | 1 |
| Izuhara, K | 1 |
| Wakahara, K | 1 |
| Hashimoto, N | 1 |
| Hahn, J | 1 |
| Appel, H | 1 |
| Scheithauer, MO | 1 |
| Petereit, F | 1 |
| Greve, J | 1 |
| Lindemann, J | 1 |
| Hoffmann, TK | 1 |
| Veit, JA | 1 |
| Sommer, F | 1 |
| Luskin, K | 1 |
| Busse, WW | 1 |
| Chen, YS | 1 |
| Locke, TB | 4 |
| Kuan, EC | 1 |
| Ig-Izevbekhai, KI | 3 |
| Kalaf, LT | 1 |
| Yip, J | 1 |
| Cottrell, J | 1 |
| Sykes, J | 1 |
| Lee, JK | 1 |
| Chaaban, MR | 1 |
| Moffatt, D | 1 |
| Wright, AE | 1 |
| Cowthran, JA | 1 |
| Hsu, ES | 1 |
| Schlosser, RJ | 1 |
| Malfitano, MJ | 1 |
| Santarelli, GD | 1 |
| Gelpi, M | 1 |
| Brown, WC | 1 |
| Stepp, WH | 1 |
| Hernandez, S | 1 |
| Kimple, AJ | 1 |
| Sweis, AM | 3 |
| Lin, TC | 2 |
| Gleeson, PK | 2 |
| Civantos, AM | 3 |
| Corr, AM | 2 |
| Gakpo, DH | 1 |
| Parhar, HS | 1 |
| Salmon, MK | 1 |
| Habermann, N | 1 |
| Havel, M | 2 |
| Cameli, P | 1 |
| D'Alessandro, M | 1 |
| Bergantini, L | 1 |
| Silvestri, E | 1 |
| Romaldi, A | 1 |
| Emmi, G | 1 |
| Parronchi, P | 1 |
| Bargagli, E | 1 |
| Martin, H | 1 |
| Barrett, NA | 1 |
| Laidlaw, T | 2 |
| Kuruvilla, M | 2 |
| Balestrieri, B | 1 |
| Ramírez-Jiménez, F | 3 |
| Vázquez-Corona, A | 1 |
| Sánchez-de la Vega Reynoso, P | 1 |
| Pavón-Romero, GF | 2 |
| Jiménez-Chobillon, MA | 2 |
| Castorena-Maldonado, AR | 1 |
| Teran, LM | 4 |
| He, SC | 1 |
| Xu, YT | 1 |
| Baptist, AP | 2 |
| Borish, L | 5 |
| Campo, P | 2 |
| Cho, SH | 10 |
| Keswani, A | 1 |
| Nanda, A | 1 |
| Cook, KA | 2 |
| Domissy, A | 1 |
| Modena, BD | 1 |
| Arshi, S | 3 |
| Eslami, N | 2 |
| Nabavi, M | 3 |
| Bemanian, MH | 3 |
| Fallahpour, M | 3 |
| Shokri, S | 2 |
| Ahmadian, J | 2 |
| Molatefi, R | 2 |
| Darabi, K | 1 |
| Sedighi, GR | 1 |
| Moinfar, Z | 2 |
| Darougar, S | 2 |
| Nguyen, A | 1 |
| Wu, C | 1 |
| Kim, A | 1 |
| Divekar, R | 1 |
| Stevens, EM | 1 |
| McCarty, EB | 1 |
| Mustafa, SS | 1 |
| Vadamalai, K | 1 |
| Sowerby, LJ | 2 |
| Patel, KB | 1 |
| Schmerk, C | 1 |
| Rotenberg, BW | 2 |
| Rocha, T | 1 |
| Sommer, DD | 2 |
| Rekabi, M | 1 |
| Hashemitari, P | 1 |
| Barbi, M | 1 |
| Porcelli, SA | 1 |
| Haque, R | 1 |
| Jackson, DJ | 1 |
| Hopkins, C | 1 |
| Eid, R | 1 |
| Yan, CH | 1 |
| Stevens, W | 1 |
| Choi, Y | 3 |
| Sim, S | 1 |
| Lee, DH | 1 |
| Lee, HR | 1 |
| Ban, GY | 1 |
| Shin, YS | 1 |
| Kim, YK | 1 |
| Priyadharshini, VS | 1 |
| de Graaf, J | 1 |
| Porras Gutiérrez de Velasco, R | 1 |
| Gratziou, C | 1 |
| Cortellini, G | 1 |
| Caruso, C | 1 |
| Romano, A | 1 |
| Park, H | 1 |
| Jung, CG | 1 |
| Johal, K | 1 |
| Welch, K | 1 |
| Peters, A | 1 |
| Blanca-Lopez, N | 2 |
| Perez-Alzate, D | 1 |
| Canto, G | 2 |
| Blanca, M | 2 |
| Roldán-Alvarez, MA | 1 |
| Falfán-Valencia, R | 1 |
| Ranasinghe, VJ | 1 |
| Trope, M | 1 |
| Brooks, SG | 1 |
| Glicksman, JT | 2 |
| Parasher, AK | 2 |
| Lee, HS | 1 |
| Lyu, J | 1 |
| Son, JH | 2 |
| Choi, IS | 13 |
| Shin, HD | 15 |
| Rodríguez-Jiménez, JC | 1 |
| Moreno-Paz, FJ | 1 |
| Guaní-Guerra, E | 1 |
| Foong, NZE | 1 |
| Yii, ACA | 1 |
| Hsu, AAL | 2 |
| Schuler, CF | 1 |
| Baldwin, JL | 1 |
| Walters, KM | 1 |
| Waldram, JD | 2 |
| Lang, DM | 1 |
| Aronica, MA | 1 |
| Maierson, ES | 1 |
| Wang, XF | 1 |
| Vasas, DC | 1 |
| Hazen, SL | 1 |
| Doghramji, L | 1 |
| Brauer, D | 1 |
| Bulva, J | 1 |
| Trinh, HKT | 1 |
| Pham, DL | 1 |
| Kim, HM | 1 |
| Kim, SH | 4 |
| Hudes, G | 3 |
| Hagin, D | 1 |
| Shacham, Y | 1 |
| Kivity, S | 1 |
| Benor, S | 1 |
| Stevenson, DD | 8 |
| Bobolea, I | 3 |
| Del Pozo, V | 1 |
| Sanz, V | 1 |
| Cabañas, R | 1 |
| Fiandor, A | 2 |
| Alfonso-Carrillo, C | 1 |
| Salcedo, MÁ | 1 |
| Heredia Revuelto, R | 1 |
| Quirce, S | 4 |
| DeGregorio, GA | 1 |
| Mastalerz, L | 4 |
| Tyrak, KE | 1 |
| Ignacak, M | 2 |
| Konduracka, E | 2 |
| Mejza, F | 1 |
| Ćmiel, A | 2 |
| Buczek, M | 1 |
| Kot, A | 1 |
| Oleś, K | 2 |
| Kowalski, ML | 2 |
| Higashi, N | 7 |
| Cooper, T | 1 |
| Greig, SR | 1 |
| Zhang, H | 1 |
| Seemann, R | 1 |
| Wright, ED | 1 |
| Vliagoftis, H | 1 |
| Côté, DWJ | 1 |
| Rusznak, M | 1 |
| Peebles, RS | 1 |
| Kuhn, DM | 1 |
| Baek, DG | 1 |
| Kothari, P | 1 |
| Raby, BA | 1 |
| Sánchez-Jareño, M | 1 |
| Barranco, P | 2 |
| Padial Vilchez, MA | 1 |
| Valbuena, T | 1 |
| Lluch, M | 1 |
| Domínguez-Ortega, J | 1 |
| López-Carrasco, V | 1 |
| Förster-Ruhrmann, U | 1 |
| Behrbohm, W | 1 |
| Pierchalla, G | 1 |
| Szczepek, AJ | 1 |
| Fluhr, JW | 1 |
| Olze, H | 1 |
| Ono, E | 4 |
| Mita, H | 5 |
| Mahdavinia, M | 1 |
| Batra, PS | 1 |
| Codispoti, C | 1 |
| Li, R | 1 |
| Luo, F | 1 |
| Steinke, JW | 4 |
| Karakaya, G | 2 |
| Celebioglu, E | 2 |
| Kalyoncu, AF | 2 |
| Park, BL | 14 |
| Uh, ST | 13 |
| Ameratunga, R | 1 |
| Randall, N | 1 |
| Dalziel, S | 1 |
| Anderson, BJ | 1 |
| Liu, L | 2 |
| Huyett, P | 1 |
| Negri, J | 3 |
| Payne, SC | 3 |
| Isogai, S | 1 |
| Hayashi, M | 1 |
| Yamamoto, N | 1 |
| Morishita, M | 1 |
| Minezawa, T | 1 |
| Okamura, T | 1 |
| Hoshino, T | 1 |
| Okazawa, M | 1 |
| Imaizumi, K | 1 |
| Miller, B | 1 |
| Mirakian, R | 1 |
| Gane, S | 1 |
| Larco, J | 1 |
| Sannah, AA | 1 |
| Darby, Y | 1 |
| Scadding, G | 1 |
| Aktas, A | 1 |
| Kurt, E | 1 |
| Gulbas, Z | 1 |
| James, A | 2 |
| Daham, K | 2 |
| Backman, L | 1 |
| Brunnström, A | 1 |
| Tingvall, T | 1 |
| Kumlin, M | 2 |
| Edenius, C | 1 |
| Dahlén, SE | 2 |
| Dahlén, B | 2 |
| Claesson, HE | 1 |
| Dazy, K | 1 |
| Walters, D | 1 |
| Holland, C | 1 |
| Baldwin, J | 1 |
| Mitchell, JE | 1 |
| Skypala, I | 1 |
| Fernández-Bertolín, L | 1 |
| Mullol, J | 3 |
| Fuentes-Prado, M | 1 |
| Alobid, I | 3 |
| Roca-Ferrer, J | 3 |
| Picado, C | 5 |
| Pujols, L | 3 |
| Comert, S | 1 |
| Yucel, T | 1 |
| Erdogan, T | 1 |
| Onerci, M | 1 |
| Kim, HJ | 2 |
| Heo, JS | 1 |
| Moon, KY | 1 |
| Neighbour, H | 1 |
| Scott, DR | 1 |
| McMullan, KL | 1 |
| Kim, JH | 11 |
| Choi, GS | 1 |
| Kim, JE | 1 |
| Jin, HJ | 2 |
| Ye, YM | 2 |
| Świerczyńska-Krępa, M | 2 |
| Bochenek, G | 3 |
| Stręk, P | 3 |
| Gielicz, A | 3 |
| Plutecka, H | 2 |
| Szczeklik, A | 2 |
| Niżankowska-Mogilnicka, E | 3 |
| Shi, M | 1 |
| Shi, G | 1 |
| Tang, J | 1 |
| Kong, D | 1 |
| Bao, Y | 1 |
| Xiao, B | 1 |
| Zuo, C | 1 |
| Wang, T | 1 |
| Wang, Q | 1 |
| Shen, Y | 1 |
| Wang, H | 1 |
| Funk, CD | 1 |
| Zhou, J | 1 |
| Yu, Y | 1 |
| Blake, DM | 1 |
| Vazquez, A | 1 |
| Tomovic, S | 1 |
| Jyung, RW | 1 |
| Cho, KS | 1 |
| Soudry, E | 1 |
| Psaltis, AJ | 1 |
| Nadeau, KC | 1 |
| McGhee, SA | 1 |
| Nayak, JV | 1 |
| Hwang, PH | 2 |
| Celejewska-Wójcik, N | 3 |
| Wójcik, K | 3 |
| Januszek, R | 2 |
| Cholewa, A | 1 |
| Choi, H | 1 |
| Yoon, MG | 1 |
| Szafraniec, K | 1 |
| Kuschill-Dziurda, J | 1 |
| Dazy, KM | 1 |
| Guillén, D | 1 |
| Calderon, O | 1 |
| Heredia, R | 1 |
| Aryan, Z | 1 |
| Ito, J | 1 |
| Akiyama, K | 4 |
| Yamamoto, K | 1 |
| Kaszuba, M | 1 |
| Machado-Carvalho, L | 1 |
| Martín, M | 1 |
| Torres, R | 1 |
| Gabasa, M | 1 |
| Pezato, R | 1 |
| Holtappels, G | 1 |
| De Ruyck, N | 1 |
| Derycke, L | 1 |
| Van Crombruggen, K | 1 |
| Bachert, C | 1 |
| Pérez-Novo, CA | 1 |
| Wieczfinska, J | 1 |
| Kacprzak, D | 1 |
| Pospiech, K | 1 |
| Sokolowska, M | 1 |
| Nowakowska, M | 1 |
| Pniewska, E | 1 |
| Bednarek, A | 1 |
| Kuprys-Lipinska, I | 2 |
| Kuna, P | 2 |
| Pawliczak, R | 1 |
| Janjua, A | 1 |
| Witterick, IJ | 1 |
| Monteiro, E | 1 |
| Gupta, MK | 1 |
| Au, M | 1 |
| Nayan, S | 1 |
| Krouse, HJ | 1 |
| Krouse, JH | 1 |
| Morales, E | 1 |
| Schuster, V | 1 |
| Spivack, SD | 1 |
| Rayner-Hartley, E | 1 |
| Chou, A | 1 |
| Saw, J | 1 |
| Sedlak, T | 1 |
| Sałapa, K | 1 |
| Tyrak, K | 1 |
| Sładek, K | 2 |
| Musiał, J | 1 |
| Feng, X | 1 |
| Ramsden, MK | 1 |
| Baker, MG | 1 |
| Tan, JHY | 1 |
| Le Pham, D | 1 |
| Lee, JH | 1 |
| Tilles, SA | 1 |
| Yamashita, M | 1 |
| Smith, TL | 1 |
| Gudziol, V | 1 |
| Michel, M | 1 |
| Sonnefeld, C | 1 |
| Koschel, D | 1 |
| Hummel, T | 1 |
| Tamayev, R | 1 |
| Iammatteo, M | 1 |
| Nautsch, D | 1 |
| Lukin, D | 1 |
| Walgama, ES | 1 |
| Lee, HJ | 1 |
| Choi, JS | 2 |
| Hwang, HG | 1 |
| Schroeder, JT | 1 |
| Hamilton, RG | 1 |
| Saini, SS | 1 |
| Adkinson, NF | 1 |
| Kasper, Ł | 1 |
| Duplaga, M | 1 |
| Mortaz, E | 1 |
| Engels, F | 1 |
| Nijkamp, FP | 1 |
| Redegeld, FA | 1 |
| Sanz, ML | 1 |
| Gamboa, PM | 1 |
| Larco, JI | 1 |
| Prior, N | 1 |
| López-Serrano, MC | 1 |
| Kupczyk, M | 1 |
| Bocheńska-Marciniak, M | 1 |
| Kellner, H | 1 |
| Lee, RU | 1 |
| Ding, D | 2 |
| Dursun, AB | 1 |
| Umbreit, C | 1 |
| Virchow, JC | 1 |
| Thorn, C | 1 |
| Hörmann, K | 1 |
| Klimek, L | 1 |
| Pfaar, O | 1 |
| Kim, S | 1 |
| Kim, YJ | 3 |
| Kim, CS | 1 |
| Han, ER | 1 |
| Park, DJ | 1 |
| Kim, DE | 1 |
| Cha, JY | 1 |
| Cheong, HS | 7 |
| Jang, AS | 5 |
| Bae, JS | 10 |
| Yamaguchi, H | 3 |
| Tatsuno, S | 1 |
| Tanimoto, H | 1 |
| Oshikata, C | 1 |
| Tsurikisawa, N | 1 |
| Otomo, M | 1 |
| Maeda, Y | 1 |
| Hasegawa, M | 1 |
| Miyazaki, E | 1 |
| Kumamoto, T | 1 |
| Blumenthal, MN | 1 |
| Doña, I | 1 |
| Cornejo-García, JA | 1 |
| Torres, MJ | 1 |
| Laguna, JJ | 1 |
| Fernández, J | 1 |
| Rosado, A | 1 |
| Rondón, C | 1 |
| Agúndez, JA | 1 |
| Korosec, P | 1 |
| Mavsar, N | 1 |
| Bajrovic, N | 1 |
| Silar, M | 1 |
| Mrhar, A | 1 |
| Kosnik, M | 1 |
| Dobovišek, A | 2 |
| Fajmut, A | 2 |
| Brumen, M | 2 |
| Park, TJ | 6 |
| Chun, JY | 1 |
| Lee, JS | 5 |
| Kim, JY | 3 |
| Pasaje, CF | 9 |
| Koh, IS | 2 |
| Oh, SH | 1 |
| Kim, YH | 4 |
| Park, SM | 1 |
| Park, SW | 3 |
| Lee, YM | 1 |
| Hong, CS | 1 |
| Lee, YW | 1 |
| Lee, JY | 1 |
| Choi, BW | 5 |
| Valero, A | 2 |
| Sánchez-López, J | 2 |
| Bartra, J | 2 |
| Serrano, C | 1 |
| Muñoz-Cano, R | 2 |
| Roca, J | 1 |
| Kim, Y | 3 |
| Kim, JM | 1 |
| Kohyama, K | 1 |
| Abe, S | 2 |
| Kodaira, K | 2 |
| Yukawa, T | 2 |
| Hozawa, S | 2 |
| Morioka, J | 1 |
| Inamura, H | 1 |
| Ota, M | 1 |
| Sagara, H | 1 |
| Kurosawa, M | 2 |
| Komase, Y | 1 |
| Nakagawa, T | 1 |
| Miyazawa, T | 1 |
| Chang, JE | 1 |
| Martin-Lazaro, J | 1 |
| Kidder, MS | 1 |
| Xing, W | 1 |
| Shen, S | 1 |
| Castells, MC | 1 |
| Chhay, H | 1 |
| Lee, TH | 1 |
| Lee, EJ | 1 |
| Chung, IY | 1 |
| Rolla, G | 1 |
| Heffler, E | 1 |
| Higashi, A | 1 |
| Gaber, F | 1 |
| Lindeberg, A | 1 |
| Skedinger, M | 1 |
| Delin, I | 1 |
| Gyllfors, P | 1 |
| Shin, S | 1 |
| Oh, T | 1 |
| An, S | 1 |
| Patrignani, P | 1 |
| Dovizio, M | 1 |
| Ertl, L | 1 |
| Braunschweig, F | 1 |
| Markmann, S | 1 |
| Leunig, A | 1 |
| Gamarra, F | 1 |
| Kramer, MF | 1 |
| Song, YS | 1 |
| Yang, EM | 1 |
| Shin, SW | 1 |
| Park, J | 1 |
| Shin, H | 1 |
| Bissinger, I | 1 |
| Chen, BS | 1 |
| Virant, FS | 1 |
| Parikh, SR | 1 |
| Manning, SC | 1 |
| Garcia-Garcia, FJ | 1 |
| Perez-Gonzalez, M | 1 |
| Kikuchi, K | 1 |
| Mochizuki, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of PDG2 in the Aspirin-Induced Reactions and in the Treatment of Aspirin-Exacerbated Respiratory Disease[NCT02824523] | 40 participants (Actual) | Observational | 2016-07-31 | Completed | |||
| Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease[NCT01778465] | 7 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| A Placebo Controlled, Double-Blind Investigation of the Therapeutic Utility of Xolair (Omalizumab) for Attenuating Aspirin Induced Bronchospasm in Patients With Aspirin Exacerbated Respiratory Disease (AERD) Undergoing Aspirin Desentization[NCT00555971] | Phase 4 | 16 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)[NCT03595488] | Phase 2 | 11 participants (Actual) | Interventional | 2018-09-05 | Completed | ||
| Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease Using a Safe, Low Dose Aspirin Challenge[NCT01320072] | 29 participants (Actual) | Observational | 2010-05-31 | Terminated (stopped due to Study discontinued and closed out by IRB. PI left the institution.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Sino-Nasal Outcome Test (SNOT-22) is a validated 22-item Chronic rhinosinusitis-specific instrument which is scored using a scale where 0=No problem, 1=Very mild problem, 2=Mild or slight problem, 3=Moderate problem, 4=Severe problem, and 5=Problem as bad as it can be. Higher scores on the SNOT-22 survey items suggest worse patient functioning or symptom severity (total score range: 0-110)" (NCT01778465)
Timeframe: 14 days after commencement
| Intervention | score on a scale (Median) |
|---|---|
| Low Salicylate Diet | 44 |
| Normal Diet | 66 |
(NCT01778465)
Timeframe: 14 days after commencement
| Intervention | mmol/L (Median) |
|---|---|
| Low Salicylate Diet | 9.9 |
| Normal Diet | 15.3 |
(NCT01778465)
Timeframe: 14 days after commencement
| Intervention | pg/ml (Median) |
|---|---|
| Low Salicylate Diet | 874.05 |
| Normal Diet | 771.99 |
(NCT01778465)
Timeframe: 14 days after enrollment
| Intervention | ng/ml (Median) |
|---|---|
| Low Salicylate Diet | 0.6 |
| Normal Diet | 0.92 |
(NCT01778465)
Timeframe: 14 days after commencement
| Intervention | ng/ml (Median) |
|---|---|
| Low Salicylate Diet | 44.21 |
| Normal Diet | 23.82 |
Measurements of urinary LTE4 in association with aspirin desensitization, comparing subjects randomized to placebo with subjects randomized to omalizumab, with study drug administered for 16 weeks. Measurements were compared for respiratory reaction in placebo subjects who exhibited either upper or lower airway reaction and after 100 mg aspirin challenge dose in omalizumab subjects who were non-reactors. For this analysis, the two omalizumab subjects who had respiratory reaction were not included. (NCT00555971)
Timeframe: Approximately 24 weeks
| Intervention | pg/mg creatinine units (Mean) |
|---|---|
| Placebo | 17489 |
| Omalizumab | 1852 |
Lack of Respiratory reaction during aspirin desensitization, including Spirometry (FEV1) testing, to assess the efficacy of Xolair on attenuating aspirin induced bronchospasm in patients with AERD. (NCT00555971)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 0 |
| Omalizumab | 5 |
We will assess FEV1% change from baseline at 12 months in AERD patients who have been on aspirin treatment for 12 months (current standard of care) (NCT01320072)
Timeframe: 12 months
| Intervention | change in percent predicted FEV1 (Mean) |
|---|---|
| Aspirin-sensitive Asthmatics | 12 |
eicosanoid metabolites concentration in plasma and urine 2 h post ASA challenge (NCT01320072)
Timeframe: 2 hours
| Intervention | log-pg/mg creatinine (Mean) |
|---|---|
| Aspirin-sensitive Asthmatics | 6.91 |
| Aspirin-tolerant Asthmatics | 5.8 |
Adverse reactions defined as bronchospasm requiring endotracheal intubation. The adverse reactions will be assessed through a post challenge follow-up with the patient at baseline and 24 hours after the challenge (NCT01320072)
Timeframe: 24 hours after the challenge
| Intervention | participants (Number) |
|---|---|
| Aspirin-sensitive Asthmatics | 0 |
| Aspirin-tolerant Asthmatics | 0 |
47 reviews available for aspirin and Aspirin Induced Asthma
| Article | Year |
|---|---|
New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Basophils; Humans; Nasal Polyps; Sinusitis | 2022 |
Updates on treatment options in aspirin exacerbated respiratory disease.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Cytokines; Humans; Sinusitis | 2022 |
Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic | 2022 |
Aspirin‑induced asthma: a still evolving area of basic and clinical research.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Humans; Immunity, | 2022 |
Aspirin-Exacerbated Respiratory Disease: A Unique Case of Drug Hypersensitivity.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis | 2022 |
The Utility of Nasal Challenges to Phenotype Asthma Patients.
Topics: Allergens; Aspirin; Asthma; Asthma, Aspirin-Induced; Humans; Phenotype | 2022 |
Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase 1; Inflammation; Leukotrienes | 2023 |
Aspirin-Exacerbated Respiratory Disease and the Unified Airway: A Contemporary Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; | 2023 |
A Review of Aspirin-exacerbated Respiratory Diseases and Immunological Efficacy of Aspirin Desensitization.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Humans; Nas | 2022 |
Recent Updates in Understanding NSAID Hypersensitivity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase 2 Inhibito | 2023 |
Relationship Between Alcohol Intolerance and Aspirin-Exacerbated Respiratory Disease (AERD): Systematic Review.
Topics: Aspirin; Asthma, Aspirin-Induced; Cross-Sectional Studies; Desensitization, Immunologic; Humans; Nas | 2023 |
Aspirin-Exacerbated Respiratory Disease Polymorphisms; a review study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Humans; Polymorph | 2023 |
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Humans; Nasal Polyps | 2023 |
The chronic rhinosinusitis practice parameter.
Topics: Advisory Committees; Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Humans; | 2023 |
Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Observational Studies as Top | 2019 |
Aspirin desensitization therapy in aspirin-exacerbated respiratory disease: a systematic review.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Rhinitis; Sinu | 2020 |
NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Early Diagnosis; Humans; | 2020 |
Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease.
Topics: Adrenal Cortex Hormones; Anosmia; Aspirin; Asthma, Aspirin-Induced; Biological Products; Humans; Imm | 2020 |
Meta-analysis Exploring Sinopulmonary Outcomes of Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2021 |
Cellular interactions in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Basophils; Bronchoconstriction; Cell Communication; Cytokines; Eic | 2021 |
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy,
Topics: Administration, Oral; Algorithms; Allergens; Animals; Anti-Inflammatory Agents; Aspirin; Asthma, Asp | 2021 |
Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, | 2021 |
Clinical evaluation and diagnosis of aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans; Nasal Polyps; Sin | 2021 |
Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.
Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Cytokines; Humans; Immunity, Innate; Inflammation; Leukoc | 2021 |
Aspirin challenge and desensitization: how, when and why.
Topics: Aspirin; Asthma, Aspirin-Induced; Coronary Artery Disease; Desensitization, Immunologic; Humans; Rhi | 2017 |
Potential Biomarkers for NSAID-Exacerbated Respiratory Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Biomarke | 2017 |
Practical approach to the treatment of NSAID hypersensitivity.
Topics: Allergens; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase | 2017 |
Aspirin exacerbated respiratory disease: Current topics and trends.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arachidonic Acid; Aspirin; A | 2018 |
Aspirin-Exacerbated Respiratory Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase 1; Cycloox | 2018 |
Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Chronic Disea | 2019 |
Clinical updates in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Disease Management; Healt | 2019 |
Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Bl | 2019 |
Safety and Efficacy of Aspirin Desensitization Combined With Long-Term Aspirin Therapy in Aspirin-Exacerbated Respiratory Disease.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Duration of Therapy; Endoscop | 2020 |
Aspirin and salicylate in respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2013 |
[Bronchial asthma: progress in diagnosis and treatments. Topics: IV. Subtype/particular type/comorbidities; 4. Aspirin-exacerbated respiratory disease (AERD)].
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Comorbidity; Humans; Treatment Outcome | 2013 |
Approach to desensitization in aspirin-exacerbated respiratory disease.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Female; Humans; Nasal Polyps | 2014 |
Aspirin allergy in patients with myocardial infarction: the allergist's role.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Immun | 2014 |
Aspirin-exacerbated respiratory disease: characteristics and management strategies.
Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Rhini | 2015 |
Platelets in patients with aspirin-exacerbated respiratory disease.
Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; | 2015 |
Aspirin-exacerbated respiratory disease: an update.
Topics: Aspirin; Asthma, Aspirin-Induced; Biomarkers; Desensitization, Immunologic; Humans; Phenotype; Polym | 2017 |
Aspirin Intolerance: Experimental Models for Bed-to-Bench.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Cell Line; Human | 2016 |
Is aspirin desensitization indicated for the treatment recalcitrant chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease?
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Humans; Nasal Polyp | 2017 |
Current complications and treatment of aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit | 2016 |
Aspirin-Exacerbated Respiratory Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Aspirin; Asthma, Aspirin-Induc | 2017 |
Update on Aspirin-Exacerbated Respiratory Disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans | 2017 |
New insights on the possible role of mast cells in aspirin-induced asthma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Asthma, Aspirin-Induced; Dinopro | 2009 |
[Aspirin-Intolerance-Syndrom : a common and interdisciplinary disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Cooperative Behavior; Cyc | 2010 |
15 trials available for aspirin and Aspirin Induced Asthma
| Article | Year |
|---|---|
Omalizumab ameliorates extrarespiratory symptoms in patients with aspirin-exacerbated respiratory disease.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; | 2023 |
Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.
Topics: Adult; Aged; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Aspiri | 2020 |
Effect of low salicylate diet on clinical and inflammatory markers in patients with aspirin exacerbated respiratory disease - a randomized crossover trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Cross- | 2021 |
The Effect of Aspirin on Moderate to Severe Asthmatic Patients with Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis.
Topics: Adult; Anti-Asthmatic Agents; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Double-Blind Method | 2021 |
Omalizumab can inhibit respiratory reaction during aspirin desensitization.
Topics: Adult; Anti-Asthmatic Agents; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Bronchial Spasm; Desensi | 2018 |
Upregulation of CD11b on eosinophils in aspirin induced asthma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; CD11b Antigen; Din | 2013 |
Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study.
Topics: Administration, Oral; Adult; Aged; Allergens; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Dise | 2014 |
Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Calcium Signaling; Cyclooxygenase Inhibitors; Cysteine; Eosinophil | 2014 |
Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, I | 2015 |
Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; C | 2016 |
A novel treatment adjunct for aspirin exacerbated respiratory disease: the low-salicylate diet: a multicenter randomized control crossover trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Cross-Over S | 2016 |
Utility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease.
Topics: Administration, Oral; Adult; Allergens; Aspirin; Asthma, Aspirin-Induced; Drug Hypersensitivity; Fem | 2016 |
Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma | 2011 |
Safety of parecoxib in asthmatic patients with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase 2 Inhibito | 2011 |
Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis.
Topics: Anaphylaxis; Aspirin; Asthma, Aspirin-Induced; Biomarkers; F2-Isoprostanes; Humans | 2012 |
184 other studies available for aspirin and Aspirin Induced Asthma
| Article | Year |
|---|---|
Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Therapy; Chronic Disease; Humans; Nasal Polyps; Pilot P | 2022 |
Outcomes of aspirin exacerbated respiratory disease patients treated with aspirin desensitization and biologics.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Chronic Disease; Desensitization, Immunologic | 2022 |
Chronic Rhinosinusitis Outcomes of Patients With Aspirin-Exacerbated Respiratory Disease Treated With Budesonide Irrigations: A Case Series.
Topics: Adrenal Cortex Hormones; Aspirin; Asthma, Aspirin-Induced; Budesonide; Chronic Disease; Humans; Nasa | 2022 |
Safety, Outcomes, and Recommendations for Two-Step Outpatient Nonsteroidal Anti-Inflammatory Drug Challenges.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Drug Hypersensitivity; Fe | 2022 |
Objective validity of patient-reported symptoms in aspirin-exacerbated respiratory disease patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans; Patient Reported | 2022 |
Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin | 2022 |
Comparison of aspirin desensitization outcomes between men and women with AERD.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Female; Humans; Mal | 2022 |
Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.
Topics: Aspirin; Asthma, Aspirin-Induced; Body Mass Index; Humans; Leukotriene E4; Respiratory System; Sinus | 2022 |
Steroid affected cytokines in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Cytokines; Granulocyte-Macrophage Colony-Stimulating Factor; Human | 2022 |
Dupilumab-associated arthralgia in patients with aspirin-exacerbated respiratory disease.
Topics: Antibodies, Monoclonal, Humanized; Arthralgia; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Hu | 2022 |
Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: Efficacy, tolerability, and patient experience.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Desensitization, Immunologic; Female; Humans; | 2022 |
Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Humans; Mucus | 2022 |
Comprehensive Analysis of Nasal Polyps Reveals a More Pronounced Type 2 Transcriptomic Profile of Epithelial Cells and Mast Cells in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Eosinophilia; Epithelial Cells; Humans; Inflammat | 2022 |
Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Eicosanoids; Humans; Nasal Polyps; Prostaglandins | 2022 |
If aspirin-exacerbated respiratory disease treatment is a jigsaw puzzle, where do the aspirin and biologic pieces go?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biological Products; Huma | 2022 |
Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life.
Topics: Anosmia; Aspirin; Asthma, Aspirin-Induced; Female; Humans; Mental Health; Quality of Life; Sinusitis | 2022 |
Hypereosinophilia following aspirin desensitization for aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2022 |
Inheritance of NSAID-Exacerbated Respiratory Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Humans; Nasal Pol | 2023 |
Pediatric-onset aspirin-exacerbated respiratory disease: Clinical characteristics, prevalence, and response to dupilumab.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin | 2022 |
Type 2 biologics reduce cumulative steroid exposure in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biological Products; Huma | 2022 |
Association of ATP8B3 gene polymorphisms with aspirin-exacerbated respiratory disease in asthmatics.
Topics: 5' Untranslated Regions; Adenosine Triphosphatases; Aspirin; Asthma, Aspirin-Induced; Genome-Wide As | 2022 |
Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Di | 2023 |
Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity.
Topics: Aspirin; Asthma, Aspirin-Induced; Cross-Sectional Studies; Humans; Inflammation Mediators; Nasal Pol | 2023 |
Algorithmic Identification of Patients With Aspirin-Exacerbated Respiratory Disease Using an Electronic Health Record.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Electronic Health Records | 2023 |
Mechanistic and clinical updates in AERD: 2021-2022.
Topics: Adult; Aspirin; Asthma; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Rhinitis | 2023 |
Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Dinoprostone; Eicosanoids; Homeostasis; Humans; Leukotrie | 2023 |
Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin | 2023 |
Characterization of alcohol-induced respiratory symptoms in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Ethanol; Humans | 2023 |
Long-term clinical outcomes of aspirin-exacerbated respiratory disease: Real-world data from an adult asthma cohort.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Eosinophilia; Eosinophils; Humans; Sinusitis | 2023 |
Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth.
Topics: Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal | 2023 |
Readability and quality analysis of patient education materials in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Comprehension; Humans; Patient Education as Topic; Sinusitis | 2023 |
Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Cardiovascular Di | 2023 |
Eosinophilic granulomatosis with polyangiitis presenting as aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Churg-Strauss Syndrome; Granulomatosis with Polyangiitis; Humans; | 2023 |
Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD.
Topics: Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase Inhibitors; Eicosanoids; Humans; Hydroxyeicosatetra | 2023 |
Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
Topics: Animals; Aspirin; Asthma; Asthma, Aspirin-Induced; Diabetes Mellitus, Type 2; Glucagon-Like Peptide- | 2023 |
Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease.
Topics: Adult; Aged; Allergens; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Aspirin; Asthma, Aspirin | 2019 |
Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease.
Topics: Adult; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induc | 2019 |
Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, I | 2019 |
Perimenstrual Asthma in Aspirin-Exacerbated Respiratory Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Female; Humans; L | 2020 |
A graduated approach to management of chronic rhinosinusitis in aspirin-exacerbated respiratory disease in the era of precision medicine.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Humans; Precision Medicine; Sinusitis | 2019 |
Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Arachidonic | 2020 |
The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Bodily Secretions; Chronic Disease; Cytokines; Desensitizat | 2020 |
Intranasal ketorolac-induced pancreatitis as a complication of modified oral aspirin desensitization in a patient with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2020 |
Aspirin-Exacerbated Respiratory Disease With Allergic Fungal Rhinosinusitis: A Case Series of Overlapping Sinonasal Endotypes.
Topics: Allergens; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensitization, Immunologic; Female; | 2020 |
Aspirin-exacerbated respiratory disease: longitudinal assessment of a large cohort and implications of diagnostic delay.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Delayed Diagnosis; Humans | 2020 |
Andrew Szczeklik: From fine art, music and literature to front science.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Music; Publications | 2020 |
Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Desensit | 2020 |
Does IgE Have a Role in Aspirin-exacerbated Respiratory Disease?
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Immunoglobulin E; Leukotrienes; Omalizumab | 2020 |
A retrospective analysis of bronchiectasis in patients with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Bronchiectasis; Humans; R | 2020 |
Complete endoscopic sinus surgery followed by aspirin desensitization is associated with decreased overall corticosteroid use.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2020 |
Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Endoscopy; Humans; Nasal Polyps; Retrospective St | 2020 |
Aspirin-exacerbated respiratory disease: personalized medical and surgical approaches.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2020 |
A Comparison of Sphenoid Sinus Osteoneogenesis in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Retrospective Studies; Rhin | 2021 |
Major complications of aspirin desensitization and maintenance therapy in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Nasal Polyps; Retrospective | 2021 |
Leukotriene-Associated Rash in Aspirin-Exacerbated Respiratory Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Exanthema; Humans; Leukot | 2020 |
Age as a factor in treatment of aspirin-exacerbated respiratory disease: relationship to required aspirin maintenance dose after desensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2020 |
AERD Associated Nasal Polyposis: Efficacy of Postoperative Antileukotriene Therapy in Comparison with Aspirin Desensitization. A Retrospective Study.
Topics: Acetates; Adult; Aged; Allergens; Aspirin; Asthma, Aspirin-Induced; Cyclopropanes; Desensitization, | 2020 |
A multicenter approach to evaluate omalizumab effectiveness in Samter's triad.
Topics: Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma | 2020 |
Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, Aspirin | 2021 |
In reply: Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: Clinical perspective.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Desensitization, Immunologic; Humans | 2021 |
Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: Clinical perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biological Products; Dese | 2021 |
Macrophages and acylcarnitines: New players in aspirin-exacerbated respiratory disease?
Topics: Aspirin; Asthma, Aspirin-Induced; Carnitine; Humans; Macrophages | 2021 |
Effect of LTRA in L-ASA Challenge for Aspirin-Exacerbated Respiratory Disease Diagnosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans; Leukotriene Antag | 2021 |
[Aspirin-exacerbated respiratory disease: current diagnosis and treatment].
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Respiratory Tract Diseases; | 2020 |
Dysbiosis in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Dysbiosi | 2021 |
Aspirin Sensitivity in Patients with Moderate to Severe Asthma.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2020 |
Intranasal ketorolac, diagnosis, and desensitization for aspirin-exacerbated respiratory disease.
Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroid | 2021 |
Analysis of spirometry measurements as predictors of aspirin desensitization outcomes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2021 |
Multidisciplinary single-center outcomes compared to two-center outcomes for the treatment of aspirin exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans; Respiratory Tract | 2021 |
Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease Based on the 12-Item Short Form Survey.
Topics: Aspirin; Asthma, Aspirin-Induced; Female; Humans; Quality of Life; Retrospective Studies; Treatment | 2021 |
Perioperative management and perceived risks of sinus surgery in patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; Nasal Polyps; Rhinitis; Sinusitis | 2021 |
Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, | 2021 |
COVID-19 in a series of patients with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; COVID-19; Humans; Respira | 2021 |
Immunologic effects of aspirin desensitization and high-dose aspirin therapy in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2021 |
Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Factors; Humans | 2021 |
Effect of TGF-β1 on eosinophils to induce cysteinyl leukotriene E4 production in aspirin-exacerbated respiratory disease.
Topics: Adult; Animals; Aspirin; Asthma, Aspirin-Induced; Eosinophils; Female; Gene Expression Regulation; G | 2021 |
Transcriptome Analysis Identifies Doublesex and Mab-3 Related Transcription Factor (DMRT3) in Nasal Polyp Epithelial Cells of Patients Suffering from Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (AERD).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; E | 2021 |
Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Immunoglobulin G; Male; Middle Aged; Nasal Polyps; Respira | 2017 |
An update on the epidemiology of aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans; Nasal Polyps; Pre | 2017 |
Physiopathology and genetics in aspirin-exacerbated respiratory disease.
Topics: Antigen Presentation; Arachidonic Acid; Aspirin; Asthma, Aspirin-Induced; Genetic Association Studie | 2017 |
Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2018 |
Association analysis of ILVBL gene polymorphisms with aspirin-exacerbated respiratory disease in asthma.
Topics: Acetolactate Synthase; Adult; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Female; Forced Expirator | 2017 |
Severe life-threatening asthma precipitated by a topical nonsteroidal anti-inflammatory drug.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Albuterol; Aspirin; Asthma, Aspirin-Induc | 2018 |
Factors correlated with repeated aspirin dosing during aspirin desensitization.
Topics: Administration, Oral; Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; D | 2018 |
Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In | 2018 |
Alcohol-induced respiratory symptoms improve after aspirin desensitization in patients with aspirin-exacerbated respiratory disease.
Topics: Adult; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Ind | 2018 |
Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Biomarkers; Cell Line; Computational Biology; Cytokines; Eo | 2018 |
Comparable safety of 2 aspirin desensitization protocols for aspirin exacerbated respiratory disease.
Topics: Adult; Allergens; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Clinica | 2019 |
Mepolizumab for the treatment of aspirin-exacerbated respiratory disease associated with coronary spasm.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma, | 2019 |
A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase Inhibitors; Desensitization, Immunologic; Eosinophi | 2019 |
Aspirin desensitization in aspirin-exacerbated respiratory disease: New insights into the molecular mechanisms.
Topics: Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Cytokines; Desensitization, Immunologic; Disease Prog | 2018 |
Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease.
Topics: Acetates; Administration, Oral; Adult; Airway Obstruction; Allergens; Anti-Asthmatic Agents; Aspirin | 2019 |
A 1-Day, 90-Minute Aspirin Challenge and Desensitization Protocol in Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cyclooxygenase Inhibitors; Desensitization, Immun | 2019 |
Prostaglandin E
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Biomarkers | 2019 |
Advances in aspirin-exacerbated respiratory disease (AERD).
Topics: Aspirin; Asthma, Aspirin-Induced; Humans | 2016 |
Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis | 2018 |
Objective and subjective sinonasal and pulmonary outcomes in aspirin desensitization therapy: A prospective cohort study.
Topics: Aged; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cohort Studies; Desensitization, Immunologi | 2019 |
Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis | 2018 |
Aspirin-Exacerbated Respiratory Disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans; Sinusitis | 2018 |
Associations between TMEM196 polymorphisms and NSAID-exacerbated respiratory disease in asthma.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Female; Forc | 2019 |
Aspirin Desensitization: Faster Protocols for Busy Patients.
Topics: Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Humans; Sinusitis | 2019 |
Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In | 2019 |
Changes in Fractional Exhaled Nitric Oxide Levels After Bronchial Challenge With Aspirin in Patients With Aspirin-Induced Asthma.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Breath Tests; Bronchial Provocation Tests; Exhalation; Fema | 2019 |
[Nasal provocation with increased ASA dose: improved "non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated disease" (N‑ERD) detection rate in chronic rhinosinusitis patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Humans; | 2019 |
Mepolizumab utility in successful aspirin desensitization in aspirin-exacerbated respiratory disease in a refractory case.
Topics: Adult; Allergens; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monocl | 2019 |
Aspirin desensitization or biologics for AERD?
Topics: Aspirin; Asthma, Aspirin-Induced; Biological Products; Desensitization, Immunologic; Humans | 2019 |
Introduction: Szczeklik's contributions to our understanding of aspirin, NSAIDs, asthma, and allergy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Drug Hypersensitivity; Hi | 2013 |
Non-steroidal anti-inflammatory drug hypersensitivity in adults and the factors associated with asthma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Drug Eruptions; Dr | 2013 |
Association analysis of tapasin polymorphisms with aspirin-exacerbated respiratory disease in asthmatics.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; | 2013 |
Samter's triad in childhood: a warning for those prescribing NSAIDs.
Topics: Acetates; Adolescent; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthm | 2013 |
Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Cysteine; Cytokines; Eosinophils; Female; Humans; Interfer | 2013 |
Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease: asthma and rhinitis.
Topics: Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Female; Humans; Lysine; Male; Middle Aged; Nasal Prov | 2013 |
Cytokine expression before and after aspirin desensitization therapy in aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; CD4-Positive T-Lymphocyte | 2013 |
The influence of aspirin on release of eoxin C4, leukotriene C4 and 15-HETE, in eosinophilic granulocytes isolated from patients with asthma.
Topics: Adult; Arachidonate 15-Lipoxygenase; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Aspirin; Asthma, | 2013 |
Anaphylaxis mediated myocardial infarction in a coronary graft: a new variant of Kounis syndrome (a case report).
Topics: Aged; Anaphylaxis; Aspirin; Asthma, Aspirin-Induced; Coronary Artery Bypass; Humans; Male; Myocardia | 2013 |
Deficient glucocorticoid induction of anti-inflammatory genes in nasal polyp fibroblasts of asthmatic patients with and without aspirin intolerance.
Topics: Aspirin; Asthma, Aspirin-Induced; Drug Resistance; Fibroblasts; Gene Expression Regulation; Glucocor | 2013 |
Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease.
Topics: Adult; Aspirin; Asthma; Asthma, Aspirin-Induced; Female; Follow-Up Studies; Humans; Male; Middle Age | 2013 |
Plasma apolipoprotein H levels are different between aspirin induced respiratory diseases and aspirin tolerant asthma.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Asthma, Aspirin-Induced; beta 2-Glycoprotein I; Bio | 2014 |
Mechanisms of aspirin-intolerant asthma: identifying inflammatory pathways in the pathogenesis of asthma.
Topics: Arachidonate 15-Lipoxygenase; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Aspirin; Asthma, Aspiri | 2014 |
Clinical course of patients with aspirin-exacerbated respiratory disease: can we predict the prognosis?
Topics: Adult; Alleles; Aspirin; Asthma, Aspirin-Induced; Drug Hypersensitivity; Female; Forced Expiratory V | 2014 |
Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice.
Topics: Allergens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Differentiation; Arginase; As | 2014 |
Otologic manifestation of Samter triad.
Topics: Aspirin; Asthma, Aspirin-Induced; Female; Hearing Loss; Humans; Middle Aged; Nasal Polyps; Otitis Me | 2014 |
Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitizat | 2014 |
Induced sputum eicosanoids during aspirin bronchial challenge of asthmatic patients with aspirin hypersensitivity.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Bronchial Pr | 2014 |
Dipeptidyl-peptidase 10 as a genetic biomarker for the aspirin-exacerbated respiratory disease phenotype.
Topics: Adipokines; Adult; Aspirin; Asthma, Aspirin-Induced; Case-Control Studies; Chitinase-3-Like Protein | 2015 |
Factors associated with asthma control in patients with aspirin-exacerbated respiratory disease.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In | 2015 |
Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
Topics: Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anti-Idiotypic; Antibodie | 2015 |
Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Biomarkers; | 2016 |
Aspirin provocation increases 8-iso-PGE2 in exhaled breath condensate of aspirin-hypersensitive asthmatics.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Biomarkers | 2015 |
Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease.
Topics: Adult; Aged; Alprostadil; Aspirin; Asthma, Aspirin-Induced; Cells, Cultured; Cyclooxygenase 2; Dinop | 2016 |
The whole-genome expression analysis of peripheral blood mononuclear cells from aspirin sensitive asthmatics versus aspirin tolerant patients and healthy donors after in vitro aspirin challenge.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; DNA, Complem | 2015 |
Samter's Triad to Aspirin-Exacerbated Respiratory Disease: Historical Perspective and Current Clinical Practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-In | 2015 |
A Case of Kounis Type I in a Young Woman With Samter's Triad.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; | 2016 |
[Induced sputum supernatant prostaglandin E2 during oral aspirin challenge of asthmatic patients with and without aspirin hypersensitivity and healthy controls--pilot study].
Topics: Administration, Oral; Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Dinoprostone; Female; Gas Chrom | 2016 |
Eosinophil production of prostaglandin D
Topics: Aspirin; Asthma, Aspirin-Induced; Cells, Cultured; Cyclooxygenase Inhibitors; Eosinophils; Gene Expr | 2016 |
Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspi | 2016 |
From "Samter's Triad" to "NERD": The Long and Winding Road to Understanding Aspirin-Exacerbated Respiratory Disease.
Topics: Allergens; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase | 2016 |
Aspirin-Exacerbated Respiratory Disease: The Hunt for the "Rosetta Stone" of Respiratory Inflammation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Humans; Inflammation; Mol | 2016 |
Aspirin-exacerbated respiratory disease: Mediators and mechanisms of a clinical disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Humans | 2017 |
Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Cross-Sectional Studies; Female; Humans; L | 2017 |
Eosinophilic esophagitis as possible complication of aspirin treatment in patient with aspirin-exacerbated respiratory disease.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Eosinophilic Esophagitis; Female; Humans; Nasal Polyps | 2017 |
Association of interleukin-25 levels with development of aspirin induced respiratory diseases.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Cytokines; F | 2017 |
Response to "The Role of Surgery in Management of Samter's Triad: A Systematic Review".
Topics: Aspirin; Asthma; Asthma, Aspirin-Induced; Humans; Nasal Polyps; Sinusitis | 2017 |
Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Aspirin; Asthma, Aspirin-Induced; Baso | 2009 |
[The frequency of hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) in the population of adult asthmatics in Poland based on an epidemiological questionnaire].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Confidence Interva | 2009 |
Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Basophils; Humans; Sensitivity and Specificity; Skin Tests | 2010 |
Diagnosis of aspirin-induced asthma combining the bronchial and the oral challenge tests: a pilot study.
Topics: Administration, Oral; Adult; Allergens; Aspirin; Asthma, Aspirin-Induced; Bronchial Provocation Test | 2009 |
[Acoustic rhinometry in the evaluation of intranasal aspirin challenge].
Topics: Administration, Intranasal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin | 2010 |
[Aspirin-induced asthma in patients with osteoarthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Female; Humans; Ibuprofen | 2010 |
Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease.
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Aged; Aspirin; Asthma, Aspirin- | 2010 |
Airway responsiveness to inhaled aspirin is influenced by airway hyperresponsiveness in asthmatic patients.
Topics: Administration, Inhalation; Adolescent; Adult; Aspirin; Asthma; Asthma, Aspirin-Induced; Bronchial H | 2010 |
KIF3A, a cilia structural gene on chromosome 5q31, and its polymorphisms show an association with aspirin hypersensitivity in asthma.
Topics: Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Bronchi; Chromosomes, Human, Pair 5; Cilia; Drug Hype | 2011 |
Increase in salivary cysteinyl-leukotriene concentration in patients with aspirin-intolerant asthma.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Cross-Sectio | 2011 |
Aspirin and nonsteroidal anti-inflammatory drug intolerance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Genetic Predispos | 2010 |
Basophil responsiveness and clinical picture of acetylsalicylic acid intolerance.
Topics: Adult; Antigens, CD; Aspirin; Asthma, Aspirin-Induced; Basophil Degranulation Test; Basophils; Femal | 2011 |
Role of expression of prostaglandin synthases 1 and 2 and leukotriene C4 synthase in aspirin-intolerant asthma: a theoretical study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Bronchoconstriction; Cycl | 2011 |
Possible association of SLC22A2 polymorphisms with aspirin-intolerant asthma.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; | 2011 |
Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients.
Topics: Adolescent; Adult; Aged; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin- | 2011 |
Association of the variants in AGT gene with modified drug response in Korean aspirin-intolerant asthma patients.
Topics: Acetates; Adolescent; Adult; Aged; Algorithms; Angiotensinogen; Anti-Asthmatic Agents; Asian People; | 2011 |
Association of FANCC polymorphisms with FEV1 decline in aspirin exacerbated respiratory disease.
Topics: Adolescent; Adult; Aged; Alternative Splicing; Aspirin; Asthma, Aspirin-Induced; Fanconi Anemia Comp | 2012 |
Association analysis of C6 genetic variations and aspirin hypersensitivity in Korean asthmatic patients.
Topics: Adolescent; Adult; Aged; Alleles; Asian People; Aspirin; Asthma, Aspirin-Induced; Case-Control Studi | 2011 |
Lack of association between CD58 genetic variations and aspirin-exacerbated respiratory disease in a Korean population.
Topics: Adolescent; Adult; Aged; Asian People; Aspirin; Asthma, Aspirin-Induced; Body Mass Index; Bronchial | 2011 |
Genetic association analysis of TAP1 and TAP2 polymorphisms with aspirin exacerbated respiratory disease and its FEV1 decline.
Topics: Adolescent; Adult; Aged; Asian People; Aspirin; Asthma, Aspirin-Induced; ATP Binding Cassette Transp | 2011 |
Polymorphisms of the CYP2C19 gene in Japanese patients with aspirin-exacerbated respiratory disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Asthm | 2011 |
Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma.
Topics: Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Female; Humans; Leukotriene E4; Lipoxins; Male; Middl | 2011 |
Strategy for NSAID administration to aspirin-intolerant asthmatics in combination with PGE2 analogue: a theoretical approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Dinoprostone; Dose-Respon | 2012 |
Smoking, environmental tobacco smoke, and aspirin-exacerbated respiratory disease.
Topics: Adolescent; Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Case-Control Studies; Environmental Expos | 2012 |
Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes.
Topics: Adult; Aged; Arachidonate 5-Lipoxygenase; Aspirin; Asthma, Aspirin-Induced; Blood Platelets; Broncho | 2012 |
Association analysis of formyl peptide receptor 2 (FPR2) polymorphisms and aspirin exacerbated respiratory diseases.
Topics: Adolescent; Adult; Aged; Aspirin; Asthma, Aspirin-Induced; Body Mass Index; Case-Control Studies; Ch | 2012 |
Aspirin-exacerbated asthma: avoiding challenge is still challenging.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Female; Humans; Male; Spu | 2012 |
Potential association of DDR1 genetic variant with FEV1 decline by aspirin provocation in asthmatics.
Topics: Adolescent; Adult; Aged; Asian People; Aspirin; Asthma; Asthma, Aspirin-Induced; Bronchial Provocati | 2012 |
Challenge of isolated sputum cells supports in vivo origin of intolerance reaction to aspirin/non-steroidal anti-inflammatory drugs in asthma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-Induced; Basophils; | 2012 |
Differential gene expression profile in PBMCs from subjects with AERD and ATA: a gene marker for AERD.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, Aspirin-I | 2012 |
Potential association of DCBLD2 polymorphisms with fall rates of FEV(1) by aspirin provocation in Korean asthmatics.
Topics: Adolescent; Adult; Aged; Alleles; Asian People; Aspirin; Asthma, Aspirin-Induced; Female; Forced Exp | 2012 |
Inside platelet-leukocyte cross-talk.
Topics: Aspirin; Asthma, Aspirin-Induced; Blood Platelets; Cysteine; Female; Humans; Leukocytes; Leukotriene | 2012 |
Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Drug Hypersensitivity; Endosc | 2013 |
Effect of genetic polymorphism of ALOX15 on aspirin-exacerbated respiratory disease.
Topics: Adult; Arachidonate 15-Lipoxygenase; Asian People; Aspirin; Asthma; Asthma, Aspirin-Induced; Base Se | 2012 |
CD55 polymorphisms and risk of aspirin‑exacerbated respiratory disease.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; | 2012 |
A highly sensitive and specific genetic marker to diagnose aspirin-exacerbated respiratory disease using a genome-wide association study.
Topics: Adolescent; Adult; Aged; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma, | 2012 |
Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunolo | 2012 |
Acoustic rhinometry and aspirin nasal challenge in the diagnosis of aspirin-intolerant asthma: clinical finding and safety aspects.
Topics: Administration, Intranasal; Adult; Aspirin; Asthma, Aspirin-Induced; Feasibility Studies; Female; Fo | 2013 |
Aspirin sensitivity syndrome (Samter's Triad): an unrecognized disorder in children with nasal polyposis.
Topics: Adolescent; Aspirin; Asthma, Aspirin-Induced; Child; Diagnosis, Differential; Female; Humans; Male; | 2013 |
Signal transduction pathways (MAPKs, NF-κB, and C/EBP) regulating COX-2 expression in nasal fibroblasts from asthma patients with aspirin intolerance.
Topics: Aspirin; Asthma, Aspirin-Induced; CCAAT-Enhancer-Binding Proteins; Cyclooxygenase 2; Down-Regulation | 2012 |
Heat shock protein 70 gene polymorphisms in Japanese patients with aspirin-exacerbated respiratory disease.
Topics: Aspirin; Asthma, Aspirin-Induced; Cyclooxygenase 2 Inhibitors; Female; Genetic Predisposition to Dis | 2013 |